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 Data provide a proof of concept that the treatment with IM may be detrimental to a favorable
outcome of CML, via the enhancement of CML stem cell potential.
 Data support via the use of a different CML cell line, namely KCL22 cells, the results obtained with
K562 cells [1].1. Data
CML is a hematopoietic disease driven by the oncogenic BCR/Abl protein, a constitutively active
tyrosine kinase, therapeutically targeted by the tyrosine kinase inhibitor (TKI) imatinib-mesylate (IM).
IM is extremely efficient in ensuring remission of disease but not in preventing the risk of relapse
upon withdrawal of therapy. This is most likely due to the refractoriness to TKI of leukemia stem cells
(LSC) enriched under energy restriction (oxygen and/or glucose shortage). We previously demon-
strated that IM enhances the maintenance of CML K562 stem cell potential in the absence of glucose
[1]. Here, we extend these findings to another CML cell line, KCL22 cells, thus corroborating the proof
of concept obtained with K562 cells.
The effects of IM on KCL22 cell growth under glucose shortage are shown in Fig. 1A. Viable cell
number underwent a 3-fold increase, peaking on day 6, to decline thereafter, as expected, due to
nutrient consumption. IM addition on day 2 determined irrelevant effects until day 3, to suppress
thereafter cell growth completely. Such an outcome is in keeping with the presence of BCR/Abl
protein, the molecular target of IM, on day 2 of incubation of KCL22 cells under glucose shortage
(Fig. 1B and [2]). The effects of glucose shortage and IM treatment on the maintenance of KCL22 CML
stem cell potential in culture were then tested by Culture Repopulation Ability (CRA) assay (Fig. 1C).th and stem cell potential in the absence of glucose. (A) KCL22 cells were plated at 3 
C1) and incubated for the indicated times: (o) untreated control; () IM administered on
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ncubation in LC1, cells were washed free of drug and replated (3  104/mL) into IM-free
mented with standard glucose concentration. The maintenance of stem cell potential at
ting viable cells (trypan blue exclusion) at the indicated times of incubation in LC2. Data
dent experiments. * p o 0.05 from day 7 (two-tailed Student's t test).
S. Bono et al. / Data in Brief 20 (2018) 1901–1904 1903KCL22 cells from cultures established in the absence of glucose and treated with IM on day 2 (Liquid
Culture 1 -LC1-, shown in A) were transferred on day 14 to non-selective (standard glucose con-
centration, no IM) secondary liquid cultures (LC2), to exploit therein their repopulation potential (C).
As expected, LC1 cells did not induce culture repopulation during the early days of incubation in LC2
[3,4]. Starting from day 7 of LC2, IM-treated LC1 cells showed increased repopulation ability com-
pared to untreated cells, indicating that IM protected stem cell potential from its suppression in
glucose-free cultures.2. Experimental design, materials and methods
2.1. Cells and culture conditions
KCL22 blast-crisis CML cells were obtained from the German Collection of Cell Cultures
(Braunschweig, Germany) and cultured as described [2]. The experiments were carried out using
RPMI 1640 medium without D-glucose (Gibco by Thermo Fisher Scientific, Waltham, MA, USA). IM
was dissolved in PBS (EuroClone) and IM-untreated cultures were PBS-supplemented. Experiments
were established (3  105/mL) with exponentially-growing cells. Viable cells were counted in a
hemocytometer by trypan blue exclusion.
2.2. Culture Repopulation Ability (CRA) assay
The CRA assay is an in vitro assay that estimates the stem cell potential via cell transfer to liquid
cultures (LC2), instead of transplantation into syngeneic animals like in the cognate Marrow Repo-
pulation Ability assay in vivo [4–10]. Cells from cultures where the experimental variants are applied
(LC1), at the 14th day of incubation in LC1 were washed free of IM and replated (3  104 cells/mL) into
IM-free LC2 containing standard glucose concentration. Culture medium was never changed during
LC1 or LC2. The kinetics of viable cell number in LC2 provides an estimate of the CRA of LC1 cells.
2.3. Cell protein content analysis
Cells were washed once with ice-cold phosphate buffered saline (PBS) containing 100 mM Na3VO4.
Total cell lysates were obtained in Laemmli buffer (62.5mM Tris/HCl, pH 6.8, 10% glycerol, 0.005%
bromophenol blue, and 2% SDS). Protein concentration was determined by the BCA method (#23225,
Pierce™ BCA Protein Assay Kit by Thermo Fisher Scientific) and 50 μg protein/sample were subjected
to SDS-PAGE as described [1]. Antibodies used for Western blotting were: anti-c-Abl (K-12), rabbit
polyclonal (#sc-131, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-α-Tubulin (clone DM1A),
mouse monoclonal (#T9026, Sigma-Aldrich, St. Louis, MO, U.S.A.), IRDyes800CW- or IRDyes680-
conjugated secondary antibody (LI-CORs Biosciences, Lincoln, NE, U.S.A.) [11]. Antibody-coated
protein bands were visualized by the Odyssey Infrared Imaging System (LI-CORs Biosciences) [12].
2.4. Statistical analysis
Data are presented as mean 7 SD (unless specified otherwise) of the indicated number of inde-
pendent experiments and were compared by using the Student's t test; p values r 0.05 were con-
sidered statistically significant.Acknowledgements
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